Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.

Condition:   Bronchial Asthma
Interventions:   Drug: Intravenous magnesium sulfate;   Drug: Inhaled budesonide;   Drug: normal saline
Sponsor:   Hamad Medical Corporation
Recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

In fatal asthma attack trial, defense focuses on who shot first – Boston Globe (subscription)


Boston Globe (subscription)

In fatal asthma attack trial, defense focuses on who shot first
Boston Globe (subscription)
The defense attorney for a Boston man facing an unusual murder charge for allegedly firing a gun and causing a bystander who ran away to suffer a fatal asthma attack said Tuesday that another man was to blame because he fired his gun first. Delivering

View full post on asthma – Google News

Breathing Easier: Apple ResearchKit Aids Asthma Trial – Genetic Engineering & Biotechnology News


Genetic Engineering & Biotechnology News

Breathing Easier: Apple ResearchKit Aids Asthma Trial
Genetic Engineering & Biotechnology News
Bridges' LifeMap Solutions joined with Mount Sinai's Icahn School of Medicine to develop Asthma Help, one of five apps Apple revealed Monday when it announced ResearchKit. The software framework, to be released next month, is designed to enable …
ResearchKit partner: Apple is doing something incredible that was 'simply not Business Insider
Apple Introduces ResearchKit, Giving Medical Researchers the Tools to Business Wire (press release)
Apple Launches "ResearchKit" for Medical StudiesNBCNews.com
TechCabal –Los Angeles Times
all 415 news articles »

View full post on asthma – Google News

Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs).

Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs).

Thorax. 2015 Feb 27;

Authors: Martineau AR, MacLaughlin BD, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Kilpin K, McLaughlin D, Fletcher G, Mein CA, Hoti M, Walton R, Grigg J, Timms PM, Rajakulasingam RK, Bhowmik A, Rowe M, Venton TR, Choudhury AB, Simcock DE, Sadique Z, Monteiro WR, Corrigan CJ, Hawrylowicz CM, Griffiths CJ

Abstract
RATIONALE: Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URIs). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking.
OBJECTIVE: To conduct a randomised controlled trial of vitamin D3 supplementation for the prevention of asthma exacerbation and URI (coprimary outcomes).
MEASUREMENTS AND METHODS: 250 adults with asthma in London, UK were allocated to receive six 2-monthly oral doses of 3?mg vitamin D3 (n=125) or placebo (n=125) over 1?year. Secondary outcomes included asthma control test and St George’s Respiratory Questionnaire scores, fractional exhaled nitric oxide and concentrations of inflammatory markers in induced sputum. Subgroup analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for 34 single nucleotide polymorphisms in 11 vitamin D pathway genes.
MAIN RESULTS: 206/250 participants (82%) were vitamin D insufficient at baseline. Vitamin D3 did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91) or first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, p=0.34). No clinically important effect of vitamin D3 was seen on any of the secondary outcomes listed above. The influence of vitamin D3 on coprimary outcomes was not modified by baseline vitamin D status or genotype.
CONCLUSIONS: Bolus-dose vitamin D3 supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency.
TRIAL REGISTRATION NUMBER: NCT00978315 (ClinicalTrials.gov).

PMID: 25724847 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

Conditions:   Epistaxis;   Blood Pressure
Interventions:   Drug: Oxymetazoline 0.05%;   Drug: Phenylephrine 0.25%;   Drug: Lidocaine 1% plus epinephrine 1:100,000;   Drug: Bacteriostatic 0.9% NaCL
Sponsor:   Mayo Clinic
Recruiting – verified November 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days